Typewriter Therapeutics raises \$5 million from investors led by RA Capital Management and AN Ventures.
Cambridge, Massachusetts, USA, Tokyo, February 27, 2024 - (JCN Newswire) - Typwriter Therapeutics, which leads the development of innovative gene therapies for severe hereditary diseases, announced today that it has raised a total of \$5 million in seed funding from AN Venture Partners, RA Capital Management, and existing investor ANRI.
Dr. Haruhiko Fujiwara, co-founder and Chief Science Officer at Typwriter Therapeutics and an emeritus professor at the University of Tokyo, stated:
"As someone who has been involved in retrotransposon research for over 40 years, I am very pleased to see the technological advancements and the emerging excitement from the scientific and pharmaceutical communities reflected in the promising data, even at this early stage. This funding will enable us to expand our team, accelerate product development, and further build our unique gene therapy platform, allowing us to take an important starting position in pursuing our vision of providing groundbreaking treatments to patients."





